COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Photographer captures Tianjin's rapid transformation over the past 10 years
- The Flying Rainbow of Shanxi: Feihong Pagoda
- China rolls out new guideline to battle illegal fishing and strengthen port inspections
- Innovation transforms embroidered thangka into income source for SW China villagers
- Green spaces bloom in Shanghai, home to over 1,000 parks
- Highly efficient immigration inspection system unveiled at Tianjin airport
